Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/23/09 → 1/31/11 |
A Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) plus Temsirolimus (Torisel) versus Bevacizumab (Avastin) plus Interferon-Alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
- Rinehart, John (PI)